Bipolar Disorder Market: Global Industry Analysis and Key Trends, Market Share, Market Size

Bipolar Disorder Market size was valued at US$ 5.34 Bn. in 2020 and the total revenue is expected to grow at 2.15 % through 2021 to 2027, reaching nearly US$ 6.20 Bn.

Bipolar Disorder Market Overview:

Bipolar disorder is sometimes known as manic-depressive illness. Bipolar disorder is a mental condition in which a person's mood and activity levels swing wildly. According to certain scientists and academics, people with particular genes are more likely to develop bipolar disorder than those who do not. Children who have a parent or sibling with bipolar disorder are considerably more likely to acquire the disease than children who do not have a family history of the illness. This mental disorder is called Bipolar Disorder because of these contrasting moods, or two poles of mood. Several research projects have found that some genes have a role in the development of Bipolar Disorder. People who have a family history of bipolar disorder are more prone to develop it. This disease affects around 45 million people across the globe. It often involves both manic and depressive episodes, as well as periods of normal mood. Those who have manic periods but no depressive episodes can be diagnosed with bipolar disorder. Bipolar Disorder Market To know about the Research Methodology :- Request Free Sample Report 2020 is considered as a base year to forecast the market from 2021 to 2027. 2020’s market size is estimated on real numbers and outputs of the key players and major players across the globe. Past five years trends are considered while forecasting the market through 2027. 2020 is a year of exception and analysed specially with the impact of lockdown by region.

Global Bipolar Disorder Market Dynamics:

The growth of the market is being fueled by an increase in knowledge regarding the diagnosis and treatment of Bipolar Disease, as well as unmet needs in the treatment of the disorder. Individuals are receiving treatment as society's acceptance of mental illness grows. In addition, the improvement of technology in diagnosing genetic illnesses and the rise of therapeutic options for genetic disorders are important drivers of market maturity. Additionally, government projects such as the National Institute of Mental Health's (NIMH)-funded Bipolar Disorder Phenome Database give thorough information on the illness's indications and symptoms. This feature is expected to contribute favourably to the global Bipolar Disorder Market's growth. According to the Institute for Health Metrics and Evaluation's (IHME) Global Burden of Diseases estimates, the prevalence of bipolar disease ranges from 0.3 to 1.2 percent each country. In 2017, bipolar disorder impacted around 46 million people globally, with 52 percent of females and 48 percent of men suffering from the illness. Late adolescence or early adulthood is the typical onset age, and people with bipolar illness typically have a history of depression. Bipolar disease affects both males and women in the same proportions. The bipolar disorder market has risen as a result of the increasing number of cases of the illness and the growing necessity to adequately manage them. However, many of the medicines used to treat bipolar illness include adverse effects such as drug addiction, diabetes and cholesterol difficulties, impaired vision, liver and thyroid damage, and more. Several of the medications have also been associated to serious adverse effects in pregnant women, including renal failure and teratogenic abnormalities in the foetus. Also, bipolar disorder is frequently misinterpreted as depression or personality disorder, lowering the diagnosis and treatment rates of this mental illness. Anticonvulsant side effects, as well as the small number of licenced anticonvulsants, are hampering market growth. However, rising technological advancements, the growing use of smartphones, smartwatches, and other wearable devices, as well as huge potential in emerging economies, all lead to positive market growth.

Global Bipolar Disorder MarketGlobal Bipolar Disorder Market Segment Analysis:

Based on the Type, the global Bipolar Disorder market is sub-segmented into Bipolar I Disorder, Bipolar II Disorder and Cyclothymic Disorder. The Bipolar I Disorder segment held the largest market share of xx% in 2020. The increased frequency of chronic illness among people with rising stress levels is a crucial factor in holding the highest shares. Individuals with bipolar disorder type II become more prone to serious for depressive illnesses than dysthymia or manic episodes, and because they are often unaware of the consequences of these, they are less likely to seek treatment for it, requiring doctors to treat these symptoms. It's very tough to screen for diseases and keep track of them. Global Bipolar Disorder MarketBased on the Drug Class, the global Bipolar Disorder market is sub-segmented into Mood Stabilizer, Anticonvulsant, Antipsychotic Drug, Antidepressant Drug and Other Classes of Drug. The Antipsychotic Drug segment held the largest market share of xx% in 2020. Antipsychotic medications are used to treat psychotic symptoms such as hallucinations, delusions, and mania in people with bipolar disorder. Certain indications and symptoms may appear during a manic or severe depressive episode. Some are also used to treat bipolar depression, and some have been shown to be effective in avoiding mania or depression in the future. In bipolar patients, antipsychotics are sometimes used "off label" to treat sleeplessness, anxiety, and agitation. They are typically used in conjunction with mood-stabilizing drugs and can help to alleviate manic symptoms until the mood-stabilizing meds take effect. On their own, several antipsychotics appear to help regulate emotions. Based on the Mechanism of Action, the global Bipolar Disorder market is sub-segmented into Selective Serotonin Reuptake Inhibitor, Serotonin Norepinephrine Reuptake Inhibitor, Tricyclic Antidepressant Drug, Benzodiazepines, Beta Blockers and Others. The Serotonin Norepinephrine Reuptake Inhibitor segment held the largest market share of xx% in 2020. The variables that can be ascribed to the fact that they suppress some manic symptoms including restlessness, agitation, and sleeplessness until mood-stabilizing medicines take action are driving demand for this market. Benzodiazepines are rarely used as a first-line therapy for bipolar disorder. They may, however, be used in conjunction with other medications to reduce some manic symptoms such as restlessness, agitation, and sleeplessness until mood-stabilizing medications take action.

Global Bipolar Disorder Market Regional Insights:

North America held the largest market share of 68% in 2020. Due to an increase in the number of persons diagnosed with bipolar disease and better healthcare infrastructure, the market is expected to grow substantially throughout the forecast period. The National Alliance on Mental Illness estimates that one out of every five people in the United States suffers from mental illness at some time during the year. Severe mania and despair need hospitalization in order to protect people from killing themselves or others. Asia Pacific is expected to grow at a highest CAGR of xx% in the global Bipolar Disorder market during the forecast period. This is due to the fact that many businesses are constructing manufacturing facilities in the region. Because of the reduced prices and increased availability of qualified labour, manufacturing companies invest in Asia. Furthermore, rising bipolar disease awareness is supporting in the region's bipolar disorder market's growth. Japan, China, and India are predicted to be the fastest-growing bipolar disorder markets in Asia. The objective of the report is to present a comprehensive analysis of the global Bipolar Disorder Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also helps in understanding the global Bipolar Disorder Market dynamic, structure by analyzing the market segments and project the global Bipolar Disorder Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the global Bipolar Disorder Market make the report investor’s guide.

Global Bipolar Disorder Market Scope: Inquiry Before Buying

Global Bipolar Disorder Market
Report Coverage Details
Base Year: 2020 Forecast Period: 2021-2027
Historical Data: 2016 to 2020 Market Size in 2020: US $ 5.34 Bn.
Forecast Period 2021 to 2027 CAGR: 2.15% Market Size in 2027: US $ 6.20 Bn.
Segments Covered: by Type • Bipolar I Disorder • Bipolar II Disorder • Cyclothymic Disorder
by Drug Class • Mood Stabilizer • Anticonvulsant • Antipsychotic Drug • Antidepressant Drug • Other Classes of Drug
byMechanism of Action • Selective Serotonin Reuptake Inhibitor • Serotonin Norepinephrine Reuptake Inhibitor • Tricyclic Antidepressant Drug • Benzodiazepines • Beta Blockers • Others

Global Bipolar Disorder Market, by Region

• North America • Europe • Asia Pacific • South America • Middle East and Africa

Global Bipolar Disorder Market Key Players

• AbbVie Inc. • Allergan PLC • AstraZeneca Plc • Novartis AG • Eli Lilly and Company • Janssen Pharmaceuticals Inc. • Glaxo SmithKline Plc • Pfizer Inc. • Otsuka Holdings Co. Ltd • Gedeon Richter • Indivior • Janssen Pharmaceuticals • Lundbeck • Bristol-Myers Squibb • Johnson & Johnson • Cephalon Inc. • Repligen Corporation • Abbott Laboratories • Merck and Co., Inc. Frequently Asked Questions: 1] What segments are covered in Bipolar Disorder Market report? Ans. The segments covered in Bipolar Disorder Market report are based on Type, Drug Class, and Mechanism of Action. 2] Which region is expected to hold the highest share in the Bipolar Disorder Market? Ans. North America is expected to hold the highest share in the Bipolar Disorder Market. 3] What is the market size of Bipolar Disorder Market by 2027? Ans. The market size of Bipolar Disorder Market is expected to reach US $ 6.20 Bn. by 2027. 4] Who are the top key players in the Bipolar Disorder Market? Ans. AbbVie Inc., Allergan PLC, AstraZeneca Plc, Novartis AG, Eli Lilly and Company, and Janssen Pharmaceuticals Inc. are the top key players in the Bipolar Disorder Market. 5] What was the market size of Bipolar Disorder Market in 2020? Ans. The market size of Bipolar Disorder Market in 2020 was US $ 5.34 Bn.
1. Global Bipolar Disorder Market: Research Methodology 2. Global Bipolar Disorder Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Bipolar Disorder Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Bipolar Disorder Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • Latin America 3.12 COVID-19 Impact 4. Global Bipolar Disorder Market Segmentation 4.1 Global Bipolar Disorder Market, by Type (2020-2027) • Bipolar I Disorder • Bipolar II Disorder • Cyclothymic Disorder 4.2 Global Bipolar Disorder Market, by Drug Class (2020-2027) • Mood Stabilizer • Anticonvulsant • Antipsychotic Drug • Antidepressant Drug • Other Classes of Drug 4.3 Global Bipolar Disorder Market, by Mechanism of Action (2020-2027) • Selective Serotonin Reuptake Inhibitor • Serotonin Norepinephrine Reuptake Inhibitor • Tricyclic Antidepressant Drug • Benzodiazepines • Beta Blockers • Others 5. North America Bipolar Disorder Market(2020-2027) 5.1 Global Bipolar Disorder Market, by Type (2020-2027) • Bipolar I Disorder • Bipolar II Disorder • Cyclothymic Disorder 5.2 Global Bipolar Disorder Market, by Drug Class (2020-2027) • Mood Stabilizer • Anticonvulsant • Antipsychotic Drug • Antidepressant Drug • Other Classes of Drug 5.3 Global Bipolar Disorder Market, by Mechanism of Action (2020-2027) • Selective Serotonin Reuptake Inhibitor • Serotonin Norepinephrine Reuptake Inhibitor • Tricyclic Antidepressant Drug • Benzodiazepines • Beta Blockers • Others 5.4 North America Bipolar Disorder Market, by Country (2020-2027) • United States • Canada • Mexico 6. Asia Pacific Bipolar Disorder Market (2020-2027) 6.1. Asia Pacific Bipolar Disorder Market, by Type (2020-2027) 6.2. Asia Pacific Bipolar Disorder Market, by Drug Class (2020-2027) 6.3. Asia Pacific Bipolar Disorder Market, by Mechanism of Action (2020-2027) 6.4. Asia Pacific Bipolar Disorder Market, by Country (2020-2027) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 7. Middle East and Africa Bipolar Disorder Market (2020-2027) 7.1 Middle East and Africa Bipolar Disorder Market, by Type (2020-2027) 7.2. Middle East and Africa Bipolar Disorder Market, by Drug Class (2020-2027) 7.3. Middle East and Africa Bipolar Disorder Market, by Mechanism of Action (2020-2027) 7.4. Middle East and Africa Bipolar Disorder Market, by Country (2020-2027) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 8. Latin America Bipolar Disorder Market (2020-2027) 8.1. Latin America Bipolar Disorder Market, by Type (2020-2027) 8.2. Latin America Bipolar Disorder Market, by Drug Class (2020-2027) 8.3. Latin America Bipolar Disorder Market, by Mechanism of Action (2020-2027) 8.4 Latin America Bipolar Disorder Market, by Country (2020-2027) • Brazil • Argentina • Rest Of Latin America 9. European Bipolar Disorder Market (2020-2027) 9.1. European Bipolar Disorder Market, by Type (2020-2027) 9.2. European Bipolar Disorder Market, by Drug Class (2020-2027) 9.3. European Bipolar Disorder Market, by Mechanism of Action (2020-2027) 9.4. European Bipolar Disorder Market, by Country (2020-2027) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 10. Company Profile: Key players 10.1. AbbVie Inc 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Allergan PLC 10.3. AstraZeneca Plc 10.4. Novartis AG 10.5. Eli Lilly and Company 10.6. Janssen Pharmaceuticals Inc. 10.7. Glaxo SmithKline Plc 10.8. Pfizer Inc. 10.9. Otsuka Holdings Co. Ltd 10.10. Gedeon Richter 10.11. Indivior 10.12. Janssen Pharmaceuticals 10.13. Lundbeck 10.14. Bristol-Myers Squibb 10.15. Johnson & Johnson 10.16. Cephalon Inc. 10.17. Repligen Corporation 10.18. Abbott Laboratories 10.19. Merck and Co., Inc.

About This Report

Report ID103389
Category Healthcare
Published DateMay 2021
Updated DateDec 2021
Contact Us